公开(公告)号：US09719122B2

公开(公告)日：2017-08-01

申请号：US14415612

申请日：2013-07-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ron Milo ,  Lior Zelcbuch ,  Niv Antonovsky

IPC: C12P23/00 ,  C12N15/52 ,  C12N15/70 ,  C12N9/02 ,  C12N9/10 ,  C12N9/90 ,  C12N15/67

CPC classification number: C12P23/00 ,  C12N9/0004 ,  C12N9/001 ,  C12N9/0073 ,  C12N9/1085 ,  C12N9/90 ,  C12N15/52 ,  C12N15/67 ,  C12N15/70 ,  C12Y114/13129 ,  C12Y205/01 ,  C12Y205/01029 ,  C12Y505/01019

Abstract: A plurality of isolated polynucleotide sequences encoding enzymes of the astaxanthin pathway is disclosed. The polynucleotides include: (i) a polynucleotide which encodes Phytoene dehydrogenase (crtI) and a first transcriptional regulatory sequence; (ii) a polynucleotide which encodes Beta-lycopene cyclase (lcy-B) and a second transcriptional regulatory sequence; (iii) a polynucleotide which encodes Beta-carotene ketolase (crtW) and a third transcriptional regulatory sequence; and wherein the first, second and third regulatory sequence are selected such that the expression of the Icy-B and the crtW is greater than a level of expression of the crtI. Methods of generating astaxanthin using the plurality of polynucleotide are also disclosed as well as bacterial cells comprising high levels of astaxanthin.

公开(公告)号：US09718859B2

公开(公告)日：2017-08-01

申请号：US14392205

申请日：2014-06-24

Applicant: Ramot at Tel-Aviv University Ltd. ,  Yeda Research and Development Co. Ltd.

Inventor： Hagit Eldar-Finkelman ,  Miriam Eisenstein ,  Avital Licht-Murava

IPC: A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  A61K47/48 ,  C40B30/02 ,  G06F19/16 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  C07K7/08 ,  C40B30/02 ,  G06F19/16 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/419 ,  Y02A50/422 ,  Y02A50/423 ,  Y02A50/491

Abstract: Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are converted to inhibitors of GSK-3 upon interacting with the enzyme's catalytic site and hence act as disease-selective inhibitors for treating conditions associated with increased activity and/or expression of GSK-3. Each of the disclosed peptides is independently of no more than 15 amino acid residues, and has an amino acid sequence which comprises a ZX1X2X3Z(p) recognition motif of GSK-3, wherein Z(p) is a phosphorylated serine or threonine residue; Z is a phosphorylatable serine or threonine residue, and each of X1, X2 and X3 is independently any amino acid, as defined in the specification. Further disclosed are methods of identifying a putative substrate-competitive peptide inhibitor of GSK-3 which are effected by computational modeling and screening.

公开(公告)号：US09714268B2

公开(公告)日：2017-07-25

申请号：US14778624

申请日：2014-04-24

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Rony Seger ,  Eldar Zehorai

IPC: A61K38/10 ,  A61K38/16 ,  C07K7/06 ,  C07K7/08 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/08 ,  A61K47/48046 ,  C07K7/08

Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.

公开(公告)号：US09695402B2

公开(公告)日：2017-07-04

申请号：US15022280

申请日：2014-09-15

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Rony Seger ,  Alexander Plotnikov

IPC: A61K38/12 ,  C12N9/12 ,  A61K38/00

CPC classification number: C12N9/12 ,  A61K38/00 ,  A61K38/12 ,  A61K47/64 ,  C12N9/1205 ,  C12Y207/11 ,  C12Y207/11024

Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.

公开(公告)号：US20170145542A1

公开(公告)日：2017-05-25

申请号：US15318459

申请日：2015-06-18

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Igor LUBOMIRSKY ,  Valery KAPLAN

IPC: C22B11/06 ,  C22B3/00

CPC classification number: C22B11/06 ,  B01J19/08 ,  C01G55/005 ,  C22B11/048 ,  Y02P10/214

Abstract: A method for recovery of platinum group metals from a spent catalyst is described. The method includes crushing the spent catalyst to obtain a catalyst particulate material including particles having a predetermined grain size. The method includes subjecting the catalyst particulate material to a chlorinating treatment in the reaction zone at a predetermined temperature for a predetermined time period by putting the catalyst particulate material in contact with the chlorine containing gas. The method also includes applying an electromagnetic field to the chlorine-containing gas in the reaction zone to provide ionization of chlorine; thereby to cause a chemical reaction between platinum group metals and chlorine ions and provide a volatile platinum group metal-containing chloride product in the reaction zone. Following this, the volatile platinum group metal-containing chloride product is cooled to convert the product into solid phase platinum group metal-containing materials.

公开(公告)号：US09617331B2

公开(公告)日：2017-04-11

申请号：US14360678

申请日：2012-11-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Karina Yaniv ,  Inbal Avraham-Davidi ,  Yogev Sela

IPC: A61K38/17 ,  A61P35/00 ,  A61P35/04 ,  C07K14/775 ,  C07K16/18 ,  C12N15/113 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/18 ,  A61K38/1709 ,  C07K14/775 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12Q1/6886 ,  G01N33/57488

Abstract: A method of treating an angiogenesis related disease or disorder in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which regulates an amount of apolipoprotein B (ApoB), and/or an ability of ApoB to transcriptionally control vascular endothelial growth factor receptor 1 (VEGFR1).

公开(公告)号：US09579339B2

公开(公告)日：2017-02-28

申请号：US14866957

申请日：2015-09-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Shaul ,  Peter Tsvetkov ,  Julia Adler

IPC: A61K48/00 ,  A61K31/713 ,  C12N15/113 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/50

CPC classification number: C12N15/1137 ,  A61K31/713 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/025 ,  C12Q1/68 ,  G01N33/5011 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.

Abstract translation: 公开了一种治疗癌症的方法。 该方法包括向受试者施用治疗有效量的药物组合物，其包含诱导26S蛋白酶体复合体解离成20S组分和19S组分从而抑制26S蛋白酶体活性的试剂，其中所述药剂没有 化疗剂。

公开(公告)号：US09577125B2

公开(公告)日：2017-02-21

申请号：US14258696

申请日：2014-04-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Dan Oron ,  Zvi Deutsch ,  Lior Neeman

IPC: H01L31/06 ,  H01L31/0352 ,  C09K11/88 ,  H01L31/0232 ,  H01L31/055 ,  C09K11/54

CPC classification number: H01L31/035218 ,  C09K11/54 ,  C09K11/88 ,  H01L31/02322 ,  H01L31/055 ,  Y02E10/52

Abstract: The present invention is based on a unique design of a novel structure, which incorporates two quantum dots of a different bandgap separated by a tunneling barrier. Upconversion is expected to occur by the sequential absorption of two photons. In broad terms, the first photon excites an electron-hole pair via intraband absorption in the lower bandgap dot, leaving a confined hole and a relatively delocalized electron. The second absorbed photon can lead, either directly or indirectly, to further excitation of the hole, enabling it to then cross the barrier layer. This, in turn, is followed by radiative recombination with the delocalized electron.

Abstract translation: 本发明基于新颖结构的独特设计，其结合了由隧道屏障分隔的不同带隙的两个量子点。 上转换预期通过顺序吸收两个光子而发生。 在广义上，第一个光子通过下带隙点中的内部吸收激发电子 - 空穴对，留下受限的孔和相对离域的电子。 第二个吸收的光子可以直接或间接导致孔的进一步激发，使其能够穿过阻挡层。 这又是随着与离域电子的辐射复合。

公开(公告)号：US09512227B2

公开(公告)日：2016-12-06

申请号：US15202493

申请日：2016-07-05

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。

公开(公告)号：US09512225B2

公开(公告)日：2016-12-06

申请号：US15190160

申请日：2016-06-22

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/4155 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.